1 Min Read
Dec 5 (Reuters) - Clovis Oncology Inc:
* CLOVIS ANNOUNCES PRIORITY REVIEW DESIGNATION FOR RUCAPARIB SUPPLEMENTAL NEW DRUG APPLICATION
* FDA ASSIGNS PDUFA DATE OF APRIL 6, 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.